{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T19:36:38Z","timestamp":1791488198913,"version":"4.3.4"},"reference-count":77,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,4,3]],"date-time":"2020-04-03T00:00:00Z","timestamp":1585872000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","bmn.com","cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Parasitology"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.pt.2020.03.009","type":"journal-article","created":{"date-parts":[[2020,4,22]],"date-time":"2020-04-22T16:27:54Z","timestamp":1587572874000},"page":"560-570","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":272,"title":["Plasmodium vivax in the Era of the Shrinking P. falciparum Map"],"prefix":"10.1016","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2000-2874","authenticated-orcid":false,"given":"Ric N.","family":"Price","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Commons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine E.","family":"Battle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamala","family":"Thriemer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamini","family":"Mendis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pt.2020.03.009_bb0005","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/S0140-6736(19)31096-7","article-title":"Mapping the global endemicity and clinical burden of Plasmodium vivax, 2000\u201317: a spatial and temporal modelling study","volume":"394","author":"Battle","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.pt.2020.03.009_bb0010","doi-asserted-by":"crossref","first-page":"15","DOI":"10.4269\/ajtmh.16-0141","article-title":"Global epidemiology of Plasmodium vivax","volume":"95","author":"Howes","year":"2016","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.pt.2020.03.009_bb0015","doi-asserted-by":"crossref","first-page":"97","DOI":"10.4269\/ajtmh.2001.64.97","article-title":"The neglected burden of Plasmodium vivax malaria","volume":"64","author":"Mendis","year":"2001","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.pt.2020.03.009_bb0020","series-title":"World Malaria Report: 2013","author":"World Health Organization","year":"2013"},{"key":"10.1016\/j.pt.2020.03.009_bb0025","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.pt.2018.02.006","article-title":"Plasmodium vivax infections of Duffy-negative erythrocytes: historically undetected or a recent adaptation?","volume":"34","author":"Gunalan","year":"2018","journal-title":"Trends Parasitol."},{"key":"10.1016\/j.pt.2020.03.009_bb0030","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0007140","article-title":"Growing evidence of Plasmodium vivax across malaria-endemic Africa","volume":"13","author":"Twohig","year":"2019","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.pt.2020.03.009_bb0035","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0005516","article-title":"Defining the next generation of Plasmodium vivax diagnostic tests for control and elimination: Target product profiles","volume":"11","author":"Ding","year":"2017","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.pt.2020.03.009_bb0040","doi-asserted-by":"crossref","first-page":"997","DOI":"10.4269\/ajtmh.2007.76.997","article-title":"The risk of malarial infections and disease in Papua New Guinean children","volume":"76","author":"Michon","year":"2007","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.pt.2020.03.009_bb0045","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1093\/infdis\/jit261","article-title":"Gametocyte dynamics and the role of drugs in reducing the transmission potential of Plasmodium vivax","volume":"208","author":"Douglas","year":"2013","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.pt.2020.03.009_bb0050","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1186\/1475-2875-13-483","article-title":"Assessment of therapeutic responses to gametocytocidal drugs in Plasmodium falciparum malaria","volume":"13","author":"White","year":"2014","journal-title":"Malar. J."},{"key":"10.1016\/j.pt.2020.03.009_bb0055","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1645\/0022-3395(2002)088[0295:EIOAFW]2.0.CO;2","article-title":"Experimental infection of Anopheles farauti with different species of Plasmodium","volume":"88","author":"Collins","year":"2002","journal-title":"J. Parasitol."},{"key":"10.1016\/j.pt.2020.03.009_bb0060","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1128\/CMR.00051-10","article-title":"Epidemiology and infectivity of Plasmodium falciparum and Plasmodium vivax gametocytes in relation to malaria control and elimination","volume":"24","author":"Bousema","year":"2011","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.pt.2020.03.009_bb0065","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.pt.2004.02.001","article-title":"Plasmodium vivax transmission: chances for control?","volume":"20","author":"Sattabongkot","year":"2004","journal-title":"Trends Parasitol."},{"key":"10.1016\/j.pt.2020.03.009_bb0070","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/1475-2875-5-15","article-title":"Are insecticide-treated bednets more protective against Plasmodium falciparum than Plasmodium vivax-infected mosquitoes?","volume":"5","author":"Bockarie","year":"2006","journal-title":"Malar. J."},{"key":"10.1016\/j.pt.2020.03.009_bb0075","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1186\/1475-2875-10-297","article-title":"Determinants of relapse periodicity in Plasmodium vivax malaria","volume":"10","author":"White","year":"2011","journal-title":"Malar. J."},{"key":"10.1016\/j.pt.2020.03.009_bb0080","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/1475-2875-13-144","article-title":"Geographical variation in Plasmodium vivax relapse","volume":"13","author":"Battle","year":"2014","journal-title":"Malar. J."},{"key":"10.1016\/j.pt.2020.03.009_bb0085","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/S1473-3099(13)70095-1","article-title":"The activation of vivax malaria hypnozoites by infectious diseases","volume":"13","author":"Shanks","year":"2013","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.pt.2020.03.009_bb0090","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S1473-3099(18)30596-6","article-title":"Risk of Plasmodium vivax parasitaemia after Plasmodium falciparum infection: a systematic review and meta-analysis","volume":"19","author":"Commons","year":"2019","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.pt.2020.03.009_bb0095","series-title":"7th International Conference in Plasmodium vivax Research, Paris, France","article-title":"The risk of Plasmodium vivax parasitaemia after Plasmodium falciparum infection: an individual patient data meta-analysis","author":"Hossain","year":"2019"},{"key":"10.1016\/j.pt.2020.03.009_bb0100","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1186\/s12936-019-3087-1","article-title":"The probability of a sequential Plasmodium vivax infection following asymptomatic Plasmodium falciparum and P. vivax infections in Myanmar, Vietnam, Cambodia, and Laos","volume":"18","author":"von Seidlein","year":"2019","journal-title":"Malar. J."},{"key":"10.1016\/j.pt.2020.03.009_bb0105","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1093\/cid\/ciq249","article-title":"Plasmodium vivax recurrence following falciparum and mixed species malaria: risk factors and effect of antimalarial kinetics","volume":"52","author":"Douglas","year":"2011","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.pt.2020.03.009_bb0110","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1128\/CMR.00074-12","article-title":"Evidence and implications of mortality associated with acute Plasmodium vivax malaria","volume":"26","author":"Baird","year":"2013","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.pt.2020.03.009_bb0115","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/B978-0-12-397900-1.00003-7","article-title":"Plasmodium vivax: clinical spectrum, risk factors and pathogenesis","volume":"80","author":"Anstey","year":"2012","journal-title":"Adv. Parasitol."},{"key":"10.1016\/j.pt.2020.03.009_bb0120","doi-asserted-by":"crossref","first-page":"e00011","DOI":"10.1128\/CMR.00011-19","article-title":"8-Aminoquinoline therapy for latent malaria","volume":"32","author":"Baird","year":"2019","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.pt.2020.03.009_bb0125","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1186\/s12879-019-4497-y","article-title":"Early and late mortality after malaria in young children in Papua, Indonesia","volume":"19","author":"Patriani","year":"2019","journal-title":"BMC Infect. Dis."},{"key":"10.1016\/j.pt.2020.03.009_bb0130","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1186\/s12916-014-0217-z","article-title":"Mortality attributable to Plasmodium vivax malaria: a clinical audit from Papua, Indonesia","volume":"12","author":"Douglas","year":"2014","journal-title":"BMC Med."},{"key":"10.1016\/j.pt.2020.03.009_bb0135","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001575","article-title":"Major burden of severe anemia from non-falciparum malaria species in southern papua: a hospital-based surveillance study","volume":"10","author":"Douglas","year":"2013","journal-title":"PLoS Med."},{"key":"10.1016\/j.pt.2020.03.009_bb0140","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/S1473-3099(11)70339-5","article-title":"Adverse effects of falciparum and vivax malaria and the safety of antimalarial treatment in early pregnancy: a population-based study","volume":"12","author":"McGready","year":"2012","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.pt.2020.03.009_bb0145","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0050128","article-title":"Multidrug-resistant Plasmodium vivax associated with severe and fatal malaria: a prospective study in Papua, Indonesia","volume":"5","author":"Tjitra","year":"2008","journal-title":"PLoS Med."},{"key":"10.1016\/j.pt.2020.03.009_bb0150","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0050127","article-title":"Plasmodium vivax and mixed infections are associated with severe malaria in children: a prospective cohort study from Papua New Guinea","volume":"5","author":"Genton","year":"2008","journal-title":"PLoS Med."},{"key":"10.1016\/j.pt.2020.03.009_bb0155","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s12916-020-1497-0","article-title":"The risk of morbidity and mortality following recurrent malaria in Papua, Indonesia: a retrospective cohort study","volume":"18","author":"Dini","year":"2020","journal-title":"BMC Med."},{"key":"10.1016\/j.pt.2020.03.009_bb0160","series-title":"World Malaria Report 2019","author":"World Health Organization","year":"2019"},{"key":"10.1016\/j.pt.2020.03.009_bb0165","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/1475-2875-9-115","article-title":"Malaria in Brazil: an overview","volume":"9","author":"Oliveira-Ferreira","year":"2010","journal-title":"Malar. J."},{"key":"10.1016\/j.pt.2020.03.009_bb0170","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1590\/S0074-02762011000900015","article-title":"Epidemiology and control of malaria in Colombia","volume":"106","author":"Rodriguez","year":"2011","journal-title":"Mem. Inst. Oswaldo Cruz"},{"key":"10.1016\/j.pt.2020.03.009_bb0175","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002815","article-title":"Malaria morbidity and mortality following introduction of a universal policy of artemisinin-based treatment for malaria in Papua, Indonesia: A longitudinal surveillance study","volume":"16","author":"Kenangalem","year":"2019","journal-title":"PLoS Med."},{"key":"10.1016\/j.pt.2020.03.009_bb0180","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1186\/s12916-019-1456-9","article-title":"Differential impact of malaria control interventions on P. falciparum and P. vivax infections in young Papua New Guinean children","volume":"17","author":"Ome-Kaius","year":"2019","journal-title":"BMC Med."},{"key":"10.1016\/j.pt.2020.03.009_bb0185","doi-asserted-by":"crossref","first-page":"147","DOI":"10.4269\/ajtmh.19-0496","article-title":"Declining burden of Plasmodium vivax in a population in Northwestern Thailand from 1995 to 2016 before comprehensive primaquine prescription for radical cure","volume":"102","author":"Chu","year":"2019","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.pt.2020.03.009_bb0190","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001891","article-title":"Strategies for understanding and reducing the Plasmodium vivax and Plasmodium ovale hypnozoite reservoir in Papua New Guinean children: a randomised placebo-controlled trial and mathematical model","volume":"12","author":"Robinson","year":"2015","journal-title":"PLoS Med."},{"key":"10.1016\/j.pt.2020.03.009_bb0195","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0003595","article-title":"Modeling the dynamics of Plasmodium vivax infection and hypnozoite reactivation in vivo","volume":"9","author":"Adekunle","year":"2015","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.pt.2020.03.009_bb0200","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/B978-0-12-397900-1.00005-0","article-title":"Chemotherapeutic strategies for reducing transmission of Plasmodium vivax malaria","volume":"80","author":"Douglas","year":"2012","journal-title":"Adv. Parasitol."},{"key":"10.1016\/j.pt.2020.03.009_bb0205","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1186\/s12936-019-2886-8","article-title":"Technical and operational underpinnings of malaria elimination from Sri Lanka","volume":"18","author":"Premaratne","year":"2019","journal-title":"Malar. J."},{"key":"10.1016\/j.pt.2020.03.009_bb0210","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1093\/cid\/ciz237","article-title":"Plasmodium knowlesi malaria in Sabah, Malaysia, 2015\u20132017: ongoing increase in incidence despite near-elimination of the human-only Plasmodium species","volume":"70","author":"Cooper","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.pt.2020.03.009_bb0215","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/S1473-3099(14)70855-2","article-title":"Global extent of chloroquine-resistant Plasmodium vivax: a systematic review and meta-analysis","volume":"14","author":"Price","year":"2014","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.pt.2020.03.009_bb0220","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.trstmh.2006.06.008","article-title":"Therapeutic response of multidrug-resistant Plasmodium falciparum and P. vivax to chloroquine and sulfadoxine-pyrimethamine in southern Papua, Indonesia","volume":"101","author":"Ratcliff","year":"2007","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"10.1016\/j.pt.2020.03.009_bb0225","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa0804915","article-title":"A trial of combination antimalarial therapies in children from Papua New Guinea","volume":"359","author":"Karunajeewa","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.pt.2020.03.009_bb0230","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1093\/cid\/ciw121","article-title":"Efficacy of artesunate-mefloquine for chloroquine-resistant Plasmodium vivax malaria in Malaysia: an open-label, randomized, controlled trial","volume":"62","author":"Grigg","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.pt.2020.03.009_bb0235","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.pt.2012.08.005","article-title":"Phenotypic and genotypic characterisation of drug-resistant Plasmodium vivax","volume":"28","author":"Price","year":"2012","journal-title":"Trends Parasitol."},{"key":"10.1016\/j.pt.2020.03.009_bb0240","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1093\/infdis\/jiy484","article-title":"Recrudescence, reinfection, or relapse? A more rigorous framework to assess chloroquine efficacy for Plasmodium vivax malaria","volume":"219","author":"Popovici","year":"2019","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.pt.2020.03.009_bb0245","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1186\/s12936-019-3072-8","article-title":"Doses of chloroquine in the treatment of malaria by Plasmodium vivax in patients between 2 and 14 years of age from the Brazilian Amazon basin","volume":"18","author":"de Sena","year":"2019","journal-title":"Malar. J."},{"key":"10.1016\/j.pt.2020.03.009_bb0250","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/S1473-3099(18)30348-7","article-title":"The effect of chloroquine dose and primaquine on Plasmodium vivax recurrence: a WorldWide Antimalarial Resistance Network systematic review and individual patient pooled meta-analysis","volume":"18","author":"Commons","year":"2018","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.pt.2020.03.009_bb0255","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/S1473-3099(10)70079-7","article-title":"Artemisinin combination therapy for vivax malaria","volume":"10","author":"Douglas","year":"2010","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.pt.2020.03.009_bb0260","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002928","article-title":"The efficacy of dihydroartemisinin-piperaquine and artemether-lumefantrine with and without primaquine on Plasmodium vivax recurrence: A systematic review and individual patient data meta-analysis","volume":"16","author":"Commons","year":"2019","journal-title":"PLoS Med."},{"key":"10.1016\/j.pt.2020.03.009_bb0265","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1093\/cid\/ciy235","article-title":"Primaquine pharmacokinetics in lactating women and breastfed infant exposures","volume":"67","author":"Gilder","year":"2018","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.pt.2020.03.009_bb0270","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/1475-2875-12-112","article-title":"Review of key knowledge gaps in glucose-6-phosphate dehydrogenase deficiency detection with regard to the safe clinical deployment of 8-aminoquinoline treatment regimens: a workshop report","volume":"12","author":"von Seidlein","year":"2013","journal-title":"Malar. J."},{"key":"10.1016\/j.pt.2020.03.009_bb0275","series-title":"Guidelines for the Treatment of Malaria","author":"World Health Organization","year":"2015"},{"key":"10.1016\/j.pt.2020.03.009_bb0280","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1186\/s12936-018-2380-8","article-title":"Quantifying primaquine effectiveness and improving adherence: a round table discussion of the APMEN Vivax Working Group","volume":"17","author":"Thriemer","year":"2018","journal-title":"Malar. J."},{"key":"10.1016\/j.pt.2020.03.009_bb0285","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002379","article-title":"Unsupervised primaquine for the treatment of Plasmodium vivax malaria relapses in southern Papua: A hospital-based cohort study","volume":"14","author":"Douglas","year":"2017","journal-title":"PLoS Med."},{"key":"10.1016\/j.pt.2020.03.009_bb0290","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1186\/1475-2875-11-280","article-title":"Primaquine radical cure of Plasmodium vivax: a critical review of the literature","volume":"11","author":"John","year":"2012","journal-title":"Malar. J."},{"key":"10.1016\/j.pt.2020.03.009_bb0295","first-page":"347018","article-title":"Antirelapse efficacy of various primaquine regimens for Plasmodium vivax","volume":"2014","author":"Rajgor","year":"2014","journal-title":"Malar. Res. Treat."},{"key":"10.1016\/j.pt.2020.03.009_bb0300","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1186\/s12936-018-2472-5","article-title":"A pilot randomized controlled trial to compare the effectiveness of two 14-day primaquine regimens for the radical cure of vivax malaria in South India","volume":"17","author":"Saravu","year":"2018","journal-title":"Malar. J."},{"key":"10.1016\/j.pt.2020.03.009_bb0305","article-title":"Primaquine at alternative dosing schedules for preventing relapse in people with Plasmodium vivax malaria","volume":"7","author":"Milligan","year":"2019","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.pt.2020.03.009_bb0310","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1093\/cid\/ciy735","article-title":"Chloroquine versus dihydroartemisinin-piperaquine with standard high-dose primaquine given either for 7 days or 14 days in Plasmodium vivax malaria","volume":"68","author":"Chu","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.pt.2020.03.009_bb0315","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/S0140-6736(19)31285-1","article-title":"Short-course primaquine for the radical cure of Plasmodium vivax malaria: a multicentre, randomised, placebo-controlled non-inferiority trial","volume":"394","author":"Taylor","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.pt.2020.03.009_bb0320","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1007\/s00436-019-06210-3","article-title":"Effects of MAO-A and CYP450 on primaquine metabolism in healthy volunteers","volume":"118","author":"Ariffin","year":"2019","journal-title":"Parasitol. Res."},{"key":"10.1016\/j.pt.2020.03.009_bb0325","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2018.1449","article-title":"Association of impaired cytochrome P450 2D6 activity genotype and phenotype with therapeutic efficacy of primaquine treatment for latent Plasmodium vivax malaria","volume":"1","author":"Baird","year":"2018","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.pt.2020.03.009_bb0330","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1002\/cpt.690","article-title":"Worldwide distribution of cytochrome P450 alleles: a meta-analysis of population-scale sequencing projects","volume":"102","author":"Zhou","year":"2017","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.pt.2020.03.009_bb0335","doi-asserted-by":"crossref","DOI":"10.1093\/jtm\/tay071","article-title":"Tafenoquine receives regulatory approval in USA for prophylaxis of malaria and radical cure of Plasmodium vivax","volume":"25","author":"Tan","year":"2018","journal-title":"J. Travel. Med."},{"key":"10.1016\/j.pt.2020.03.009_bb0340","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1056\/NEJMoa1802537","article-title":"Tafenoquine versus primaquine to prevent relapse of Plasmodium vivax malaria","volume":"380","author":"Llanos-Cuentas","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.pt.2020.03.009_bb0345","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1056\/NEJMoa1710775","article-title":"Single-dose tafenoquine to prevent relapse of Plasmodium vivax malaria","volume":"380","author":"Lacerda","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.pt.2020.03.009_bb0350","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.15585\/mmwr.mm6846a4","article-title":"Guidance for using tafenoquine for prevention and antirelapse therapy for malaria \u2013 United States, 2019","volume":"68","author":"Haston","year":"2019","journal-title":"MMWR Morb. Mortal. Wkly Rep."},{"key":"10.1016\/j.pt.2020.03.009_bb0355","doi-asserted-by":"crossref","DOI":"10.5694\/mja2.50474","article-title":"Tafenoquine for the radical cure and prevention of malaria: the importance of testing for G6PD deficiency","volume":"212","author":"Commons","year":"2020","journal-title":"Med. J. Aust."},{"key":"10.1016\/j.pt.2020.03.009_bb0360","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002992","article-title":"Performance of the Access Bio\/CareStart rapid diagnostic test for the detection of glucose-6-phosphate dehydrogenase deficiency: A systematic review and meta-analysis","volume":"16","author":"Ley","year":"2019","journal-title":"PLoS Med."},{"key":"10.1016\/j.pt.2020.03.009_bb0365","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0206331","article-title":"Field evaluation of quantitative point of care diagnostics to measure glucose-6-phosphate dehydrogenase activity","volume":"13","author":"Alam","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.pt.2020.03.009_bb0370","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1093\/infdis\/jiz052","article-title":"Plasmodium vivax relapse rates following Plasmodium falciparum malaria reflect previous transmission intensity","volume":"220","author":"Ashley","year":"2019","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.pt.2020.03.009_bb0375","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.pt.2004.03.006","article-title":"Mixed-species malaria infections in humans","volume":"20","author":"Mayxay","year":"2004","journal-title":"Trends Parasitol."},{"key":"10.1016\/j.pt.2020.03.009_bb0380","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s12936-017-1784-1","article-title":"Challenges for achieving safe and effective radical cure of Plasmodium vivax: a round table discussion of the APMEN Vivax Working Group","volume":"16","author":"Thriemer","year":"2017","journal-title":"Malar. J."},{"key":"10.1016\/j.pt.2020.03.009_bb0385","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/S0140-6736(19)31097-9","article-title":"Mapping the global prevalence, incidence, and mortality of Plasmodium falciparum, 2000\u201317: a spatial and temporal modelling study","volume":"394","author":"Weiss","year":"2019","journal-title":"Lancet"}],"container-title":["Trends in Parasitology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S147149222030074X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S147149222030074X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T20:18:00Z","timestamp":1739305080000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S147149222030074X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":77,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["S147149222030074X"],"URL":"https:\/\/doi.org\/10.1016\/j.pt.2020.03.009","relation":{},"ISSN":["1471-4922"],"issn-type":[{"value":"1471-4922","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Plasmodium vivax in the Era of the Shrinking P. falciparum Map","name":"articletitle","label":"Article Title"},{"value":"Trends in Parasitology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pt.2020.03.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}